Abstract
No public abstract is available from the verified source records.
Cédric Schraepen
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
openalex
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Preoperative versus postoperative chemoradiotherapy for rectal cancer
10.1056/nejmoa040694 · 2004
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial
10.1016/s1470-2045(21)00079-6 · 2021
Short-course radiotherapy followed by chemotherapy before total mesorectal excision versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial
10.1016/s1470-2045(20)30555-6 · 2021
Adjuvant chemotherapy for rectal cancer
10.1093/annonc/mdq616 · 2010
Association between adjuvant chemotherapy and survival in patients with rectal cancer and pathological complete response after neoadjuvant chemoradiotherapy and resection
10.1038/s41416-020-0989-1 · 2020
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results
10.1097/01.sla.0000141194.27992.32 · 2004
Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for patients with locally advanced rectal cancer: long-term results of the CAO/ARO/AIO-12 randomized clinical trial
10.1001/jamaoncol.2021.5445 · 2022
Preliminary results of the organ preservation of rectal adenocarcinoma (OPRA) trial
10.1200/jco.2020.38.15_suppl.4008 · 2020
Multicenter randomized phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR)
10.1200/jco.21.01667 · 2022
Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12
10.1200/jco.19.00308 · 2019
Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study
10.1093/annonc/mdz186 · 2019
MRI-diagnosed tumour deposits and EMVI status have superior prognostic accuracy to current clinical TNM staging in rectal cancer
10.1097/sla.0000000000004499 · 2022
Intentional watch-and-wait or organ preservation surgery following neoadjuvant chemoradiotherapy plus consolidation CAPEOX for MRI-defined low-risk rectal cancer: findings from a prospective phase 2 trial (PKUCH-R01)
10.1097/sla.0000000000005507 · 2023
Mucinous adenocarcinoma of the rectum: a poor candidate for neo-adjuvant chemoradiation?
2014
Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-year follow-up of the RAPIDO trial
10.1097/sla.0000000000005799 · 2023
Short-course radiotherapy versus long-course radio-chemotherapy as neoadjuvant treatment for locally advanced rectal cancer: meta-analysis from a toxicity perspective
2021
How to measure tumour response in rectal cancer? An explanation of discrepancies and suggestions for improvement
10.1016/j.ctrv.2020.101964 · 2020
Preoperative radiotherapy with a simultaneous integrated boost compared to chemoradiotherapy for cT3–4 rectal cancer: long-term results of a multicenter randomized study
10.3390/cancers15153869 · 2023
Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early rectal adenocarcinoma (OPERA): a phase 3 randomised controlled trial
10.1016/s2468-1253(22)00392-2 · 2023
Watch-and-wait management for rectal cancer after clinical complete response to neoadjuvant therapy
10.1016/j.yasu.2021.05.007 · 2021
Does the gain of total neoadjuvant therapy outweigh the harm in rectal cancer? Importance of the ATRESS phenomenon: a systematic review
10.3390/cancers15041016 · 2023
Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer (GRECCAR-6)
10.1200/jco.2016.67.6049 · 2016
Optimized tools and timing of response reassessment after neoadjuvant chemoradiation in rectal cancer
10.1007/s00384-022-04268-7 · 2022
Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer
10.1002/bjs.9112 · 2013
A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker (TRIGGER)
10.1186/s13063-017-2085-2 · 2017
Importance of patient reported and clinical outcomes for patients with locally advanced rectal cancer and their treating physicians
10.1016/j.ejso.2020.04.014 · 2020
Patient and physician preferences for nonoperative management for low rectal cancer: is it a reasonable treatment option?
10.1097/dcr.0000000000001166 · 2018
Neoadjuvant and adjuvant therapy for local excision of rectal cancer
10.1016/j.scrs.2022.100900 · 2022
Burden of disease experienced by patients following a watch-and-wait policy for locally advanced rectal cancer: a qualitative study
10.1111/codi.15838 · 2021
Burden of disease experienced by patients following a watch-and-wait policy for locally advanced rectal cancer: a qualitative study
10.1111/codi.15838 · doi-reference
Neoadjuvant and adjuvant therapy for local excision of rectal cancer
10.1016/j.scrs.2022.100900 · doi-reference
Patient and physician preferences for nonoperative management for low rectal cancer: is it a reasonable treatment option?
10.1097/dcr.0000000000001166 · doi-reference
Importance of patient reported and clinical outcomes for patients with locally advanced rectal cancer and their treating physicians
10.1016/j.ejso.2020.04.014 · doi-reference
A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker (TRIGGER)
10.1186/s13063-017-2085-2 · doi-reference
Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer
10.1002/bjs.9112 · doi-reference
Optimized tools and timing of response reassessment after neoadjuvant chemoradiation in rectal cancer
10.1007/s00384-022-04268-7 · doi-reference
Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer (GRECCAR-6)
10.1200/jco.2016.67.6049 · doi-reference
Does the gain of total neoadjuvant therapy outweigh the harm in rectal cancer? Importance of the ATRESS phenomenon: a systematic review
10.3390/cancers15041016 · doi-reference
Watch-and-wait management for rectal cancer after clinical complete response to neoadjuvant therapy
10.1016/j.yasu.2021.05.007 · doi-reference
Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early rectal adenocarcinoma (OPERA): a phase 3 randomised controlled trial
10.1016/s2468-1253(22)00392-2 · doi-reference
Preoperative radiotherapy with a simultaneous integrated boost compared to chemoradiotherapy for cT3–4 rectal cancer: long-term results of a multicenter randomized study
10.3390/cancers15153869 · doi-reference
How to measure tumour response in rectal cancer? An explanation of discrepancies and suggestions for improvement
10.1016/j.ctrv.2020.101964 · doi-reference
Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-year follow-up of the RAPIDO trial
10.1097/sla.0000000000005799 · doi-reference
Intentional watch-and-wait or organ preservation surgery following neoadjuvant chemoradiotherapy plus consolidation CAPEOX for MRI-defined low-risk rectal cancer: findings from a prospective phase 2 trial (PKUCH-R01)
10.1097/sla.0000000000005507 · doi-reference
MRI-diagnosed tumour deposits and EMVI status have superior prognostic accuracy to current clinical TNM staging in rectal cancer
10.1097/sla.0000000000004499 · doi-reference
Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study
10.1093/annonc/mdz186 · doi-reference
Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12
10.1200/jco.19.00308 · doi-reference
Multicenter randomized phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR)
10.1200/jco.21.01667 · doi-reference
Preliminary results of the organ preservation of rectal adenocarcinoma (OPRA) trial
10.1200/jco.2020.38.15_suppl.4008 · doi-reference
Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for patients with locally advanced rectal cancer: long-term results of the CAO/ARO/AIO-12 randomized clinical trial
10.1001/jamaoncol.2021.5445 · doi-reference
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results
10.1097/01.sla.0000141194.27992.32 · doi-reference
Association between adjuvant chemotherapy and survival in patients with rectal cancer and pathological complete response after neoadjuvant chemoradiotherapy and resection
10.1038/s41416-020-0989-1 · doi-reference
Adjuvant chemotherapy for rectal cancer
10.1093/annonc/mdq616 · doi-reference
Short-course radiotherapy followed by chemotherapy before total mesorectal excision versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial
10.1016/s1470-2045(20)30555-6 · doi-reference
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial
10.1016/s1470-2045(21)00079-6 · doi-reference
Preoperative versus postoperative chemoradiotherapy for rectal cancer
10.1056/nejmoa040694 · doi-reference